BioVaxys Technology Corp.
BVAXF
$0.0321
$0.003512.24%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 86.74% | 36.31% | 11.52% | -19.11% | -22.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.03% | 28.75% | -1.44% | -33.22% | -41.92% |
| Operating Income | -87.03% | -28.75% | 1.44% | 33.22% | 41.92% |
| Income Before Tax | 12.67% | 49.32% | 74.27% | 56.22% | 46.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.67% | 49.32% | 74.27% | 56.22% | 46.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.67% | 49.32% | 74.27% | 56.22% | 46.82% |
| EBIT | -87.03% | -28.75% | 1.44% | 33.22% | 41.92% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 47.69% | 72.15% | 82.70% | 68.45% | 60.65% |
| Normalized Basic EPS | 57.89% | 67.28% | 67.26% | -18.79% | -6.74% |
| EPS Diluted | 47.69% | 72.15% | 82.70% | 68.45% | 60.65% |
| Normalized Diluted EPS | 57.89% | 67.28% | 67.26% | -18.79% | -6.74% |
| Average Basic Shares Outstanding | 64.34% | 52.10% | 44.57% | 43.98% | 36.97% |
| Average Diluted Shares Outstanding | 64.34% | 52.10% | 44.57% | 43.98% | 36.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |